Biogen Idec and UCB have signed exclusive pharma alliance agreements granting UCB the right to commercialize Biogen Idec products.
The pharma alliance is for the following countries: South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Biogen Idec will supply UCB with its portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA, FAMPYRA, AVONEX, TYSABRI, PLEGRIDY and Daclizumab High-Yield Process (DAC HYP).
The relationship also includes ELOCTATE and ALPROLIX, Biogen Idec’s investigational long-acting recombinant candidates for hemophilia A and B, respectively.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Biogen Idec
Report: Partnering Deals and Alliances with Big Biotech
Report: Merger and Acquisition Terms and Agreements
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity